Journal
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM
Volume 23, Issue 2, Pages 129-133Publisher
WILEY
DOI: 10.1111/jns.12271
Keywords
chemotherapy; neuropathy; nutrition; paxlitaxel; risk factors; toxic
Categories
Funding
- Evergreen Invitational Women's Health Initiative
Ask authors/readers for more resources
Peripheral neuropathy is a common side effect of many chemotherapeutic agents including paclitaxel. We prospectively evaluated demographic and laboratory data in a cohort of 61 woman with breast cancer prior to paclitaxel exposure to explore factors that predispose to neuropathy development. Neuropathy was graded based on the total neuropathy score reduced version (rTNS) at baseline and at 4 months after initiation of chemotherapy. A multivariate analysis identified predictors with the strongest association with a change in rTNS. Serum albumin (P = .002), paclitaxel dose (P = .001), and body surface area (P = .006) were statistically significantly associated with a positive rTNS change (worsening neuropathy). These results suggest that poor nutritional status and obesity increase the risk of paclitaxel induced neuropathy, and that screening for these factors prior to chemotherapy exposure may improve early neuropathy detection or decrease risk with dietary modifications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available